- Home
- MTNB
as 02-05-2025 9:40am EST
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | BEDMINSTER |
| Market Cap: | 3.0M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.52 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.48 - $21.50 | Next Earning Date: | 03-26-2025 |
| Revenue: | N/A | Revenue Growth: | -65.62% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Matinas Biopharma Holdings Inc. News
MTNB Breaking Stock News: Dive into MTNB Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Matinas BioPharma Receives NYSE Noncompliance Notice
MT Newswires
3 months ago
Top Midday Decliners
GlobeNewswire
3 months ago
Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction
GuruFocus.com
3 months ago
Highbridge Capital Management's Strategic Acquisition in Matinas BioPharma
TipRanks
5 months ago
Upcoming Stock Splits This Week (September 2 to September 6) – Stay Invested
GlobeNewswire
6 months ago
Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update
GlobeNewswire
6 months ago
Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024
GlobeNewswire
7 months ago
Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program
Compare MTNB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MTNB Matinas Biopharma Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.